Rousseau E, Wilson D, Lacroix-Poisson F, et al. - In this prospective study, persons with prostate cancer and biochemical recurrence following radical prostatectomy or curative-intent radiotherapy were involved in order to assess the safety, sensitivity, and influence on patient management of ¹⁸F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) in the setting of biochemical recurrence of prostate cancer. One hundred thirty cases were assessed. For the localization of biochemical recurrence of prostate cancer, ¹⁸F-DCFPyL PET/CT was discovered to be reliable and sensitive. Therefore, this test enhanced decision making for referring oncologists and modified management for most cases.